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INTRODUCTION 
Vitiligo is an acquired common pigmentary disorder clinically 
characterized  by the development of  depigmented macules which are 
caused by the destruction of  melanocytes  in the affected areas . This is 
described in the Hindu sacred book ATTARVA VEDA in 1400 B.C.  
This had been often confused with leprosy .This misconception among 
the people is the basis for the social stigma tagged with this disease. In 
certain culture, patients with vitiligo are still regarded as social outcasts. 
 About 0.5 – 1 % of general population suffer from vitiligo. Half 
of all the patients develop the disease before the age of twenty.  Onset at 
an old age occurs but is unusual and should raise concern about 
underlying disorders or associated diseases52.  
Generalized vitiligo is the most common clinical presentation and 
commonly involves the face and acral area. Vitiligo is not a life 
threatening disease and does not require treatment unless severe 
cosmetic disfigurement causes emotional and social distress9.   
Most often, depigmentation is gradually progressive process but 
in generalized vitiligo , patients may report  a sudden onset with rapid 
spread of vitiligo over a period of few months . Subsequently the disease 
2 
 
may remain quiescent for many years. Upto thirty percent of the patients 
report “spontaneous” repigmentation, which appears in perifollicular 
and marginal areas of sun exposed lesions during the summer months.  
Complete sunlight induced repigmentation is extremely rare. 
Independently of the initial course of the disease, vitiligo may come to a 
halt and remain stable for decades. Focal and segmental vitiligo usually 
do not extend beyond their initial regional distribution, and once the 
expansion stops, they tend to be quite stable .Segmental vitiligo can also 
occur as a distinctive part of generalized disease and may precede its 
onset10. At present there is no universally effective drug for vitiligo 
therapy.   The various treatment modalities include steroids (topical and 
systemic),  cyclophosphamide  pulse, and clofazamine , placentrex 
(topical and injection) , autologous melanocyte transplant, choloroquine,  
Khellin – UVA(KUVA), PAUVA (Lphenylalanine + UVA), 
fluorouracil (topical), tacrolimus  induce temporary clearance with 
recurrence after variable intervals14,41. 
Of several therapeutic options available one of the promising 
therapies is PUVA (Psoralen and UVA). This is based on the 
observation that in many patients sun exposed lesions tend to show 
follicular repigmentation during the summer months. 
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With the increased sensitivity of vitiligo to sun burn and the 
unpredictable dosimetry with natural sunlight, solar phototherapy as not 
evolved into a true therapeutic option. On the other hand, first 
description of vitiligo treatment with what can be considered photo 
chemotherapy dated back about 4000 years which makes PUVA one of 
the oldest therapeutic principles that are still in use in the 21st century. 
Heliotherapy (sunlight therapy) was first introduced by   
Herodotus; a renowned Greek physician of the 2nd century B.C has been 
called the Father of Heliotherapy7.  
Indians used the tropical plant  extract (Psoralea  corylifolia) 
combined  with subsequent sun exposure as early as 1400 B.C. Later 
around 12th century A.D., the Egyptians used Psoralen obtained from 
another plant Ammi majus7. 
Photo chemotherapy of vitiligo was revived for modern medicine 
of a century ago when El Mofty published the success of his therapeutic 
trial and subsequently identified the Psoralen as the active compound. 
Kelly and Pinkus reported some success in treating vitiligo with 
oral administration of 8-MOP followed by sunlight exposure. Since 
natural sunlight lacks predictability often changing emission spectrum, 
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changing its output as day progresses, in 1960 it was realized  that  
8-MOP  optimally sensitizes the vitiliginous skin at 360 nm., the UV 
light box was born7. 
In 1974 Parrish et al successfully treated generalized Psoriasis 
with oral 8-MOP and high intensity UVA therapy and coined the term 
(acronym), PUVA8. 
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AIM 
1) To evaluate the efficacy of therapeutic effect of oral psoralen 
followed by Ultraviolet - A  irradiation (PUVA) for chronic vitiligo 
patients who failed to respond to other modalities of treatment for 
vitiligo 
2) To assess the efficacy of PUVA response at various sites involved. 
3) To study the Age, Sex, Family History, Koebnerization, surface 
area of involvement and their influence on the PUVA response. 
4) To study the association between blood group and its efficacy on 
PUVA therapy. 
5) To assess the complication due to PUVA therapy. 
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REVIEW OF LITERATURE  
HISTORICAL ASPECTS 
 The word vitiligo might have evolved from the Latin word 
“vitium” meaning a defect / blemish.   Vitelius signifying a calf’s white 
patches. Documentation of the use of the word vitiligo occurred in the 
first century A.D. by the Roman physician ‘Celus’. 
 Indian literature dating to 1500 to 1000 B.C. refers to the word 
“kilas” (‘kil’ means white, ‘as’ means to caste) .Palita (‘pal’ implies 
grey, old and aged) referring to white patches on the skin. In the sacred 
book of Buddhism ‘Vinay Pitak’  (621-544 B.C ) , persons suffering 
from kilas were unable to be ordained63. 
EPIDEMIOLOGY 
 Vitiligo   occurs all over the world and in all races, it accounts for 
about 0.5 –1% of general population59. In India the incidence is as high 
as 8.8%3. Family history is noticed in 20-30% of cases59.  Inheritance is 
thought to be polygenic or autosomal dominant with incomplete 
penetrance and variable expression59. It is more in monozygotic twins 
than in dizygotic twins.  Incidence in Caucasians is 1%. Both sexes are 
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equally affected.  Vitiligo may develop at any age and onset has been 
reported from birth to 81 years of age. The peak age of onset is between 
10 –30 years.  Half of them manifest before 20 years28.  Segmental 
vitiligo appears notably familial53. HLA DR A1 , 0302 , HLA DQ A1, 
0601, DQ B1 ,0803 , DR B1-0503 alleles predispose individuals to 
vitiligo and HLA DR A1 6501 alleles protect individuals from vitiligo60.  
HLA B13 is associated with vitiligo and antithyroid antibodies62. 
AETIOLOGY 
The exact aetiology is unknown. So various theories are proposed 
namely,  
1. Autoimmune theory. 
2. Neural hypothesis. 
3. Self destruction hypothesis. 
4. Other prevailing hypothesis. 
AUTOIMMUNE THEORY 
 In vitiligo autoantibodies are directed against various melanocytic 
proteins including tyrosinase related proteins 1, 2 which correlate with 
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the disease activity. In progressive vitiligo increased levels of CLA, 
active CD8 + T cell in the peripheral blood of the patient28.  
 Several autoimmune diseases have been associated with vitiligo 
such as Hypothyroidism16, Hashimoto’s thyroiditis (20-30%)44, 
pernicious anaemia52 (4-20%), Addisons disease37 hypogonadism44, 
halonaevus, scleroderma, lichen planus, DLE, rheumatoid arthritis, 
alopecia areata3. 
 Vitiligo is more often associated with late onset diabetes 
mellitus56. Diabetes mellitus both juvenile onset and adult onset types 
occurs in 1- 7.1% of vitiligo patients and conversely vitiligo occurs in 
4.8% of diabetic patients28. 
 Autoimmune poly endocrinopathy, candidiasis, ectodermal 
dystrophy (APECED) with gene mutation in AIRE (autoimmune 
regulator) has been increasingly associated with vitiligo52.  The presence 
of an auto immune reaction of uveal tract along with the meningeal, 
cochlear epidermal melanin in Vogt-Koyanaki-Harada Syndrome 
leading to destruction of melanin support the role of immune response in 
vitiligo49.  
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A non-cytotoxic antikeratinocyte intracellular bodies directed 
against 40 KD or 75 KD common tissue antigens and 65 KD and 90 KD 
pigment cell specific antigens correlate with the disease activity and 
more pronounced in active rather than stable vitiligo63. 
 In Neural Hypothesis,  increased immune reactivity of 
neuropeptide Y/ altered balance of nerve growth factor receptors lead to 
increased expression of catechol –o-ethyl transferase and mono amino 
oxidase and Beta 2 adreno receptors28.  
Studies has shown that disturbance of the autonomous nervous 
system leading to depigmentation may lead to vaso constriction. 
1. Clinical evidence of segmental and dermatomal vitiligo. 
2. Increased sweating and vaso constriction in vitiliginous areas 
implies increased adrenergic activity. 
3. Elevated levels of tumour necrosis factor α (TNFα), intercellular 
adhesion molecule –1 (ICAM 1) and Interferon γ have been 
found in perilesional skin in the vitiligo patients64. 
Degenerative and regenerative changes were found in the 
terminal regions of the small proportion of the nerve supplying central 
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and marginal regions of vitiliginous lesions indicating that affected 
nerves were auto immune in function6. 
SELF DESTRUCTION HYPOTHESIS: 
 A.B. Lerner states that loss of intrinsic protective mechanism that 
eliminate toxic intermediate metabolite in the melanocytic pathways 
leads to the accumulation of 5,6,7,8, tetrahydrobiopterin which increase 
the production of hydrogen peroxide28. 
OTHER PREVAILING HYPOTHESIS: 
1) Intrinsic defect of structure and function of rough endoplasmic 
reticulum in vitiligo melanocytes. 
2)  Deficiency in melanocyte growth factor.  
3) Dysregulation of melanocyte apoptosis. 
4) Primary disturbance in T cell resulting in the development of 
forbidden clones of auto reactive lymphocytes in the epidermis28. 
In Vitiligo, onset of the activity often attributes to emotional 
stress which causes increased release of catecholamines from nerve 
endings19. 
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Studies have shown that reduced zinc level significantly 
correlates with   vitiligenous lesion61. 
Lower level of catalase and UV induced damage to the epidermis 
release free reactive oxygen species which are cytotoxic to melanocytes 
and also inhibit tyrosinase32. 
Emotional factors, physical injury, sunburn are often associated 
with the onset of the disease19. 
Spontaneous repigmentation was due to the release of cytokine 
from the donor site when stimulating the vitiliginous patch and hair 
follicle of the grafted site65.         
CLASSIFICATION OF VITILIGO (after Fitzpatrick 1987)58,29: 
VITILIGO 
                       
 
  
                                                                                                
                                                                                                   
 
Localised Generalised     Mixed 
Focal Segmental 
Acrofacial 
Vitiligo Vulgaris 
Universal Vitiligo 
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1. LOCALISED: 
Focal –one or more patches, non dermatomal distribution 
Segmental –one or more patches in dermatomal distribution. 
2. GENERALISED  
a. Acrofacial – Acral (hands and feet)  
 Orificial (around mouth and genitals, eyes, nose and ears)  
  Lip tip  (Acral, nipple, genital, lips) 
b. Vulgaris    -  Scattered patches in symmetrical or asymmetrical  
                      distribution 
c. Universal -   Total or near total. 
2. Mixed  - 
 Segmental with acro-orificial or vulgaris  
Trichrome vitiligo – 
 Uniform, narrow, hypopigmented zone between normally 
pigmented skin and the typical vitiligo macules 51. 
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 A trichrome lesion naturally evolves to a typical white vitiligo 
macule or macules albeit not at a predictable rate.  Trichrome vitiligo 
occurred mostly on the trunk in active vitiligo vulgaris28. Focal vacuolar 
degeneration of the basal cell layer and mild inflammatory cell infiltrate 
of epidermis and dermis were prominent in the light brown skin and 
perilesional normal skin than in other normal area of the skin. Decreased 
number of melanocytes in the tanned skin compared with vitiliginous 
skin is observed24.  
1. Quadrichrome Vitiligo : 
 It refers to the fourth colour. This is a marginal hyper-
pigmentation in addition to trichrome vitiligo. 
2. Pentachrome Vitiligo  : 
 It has white, tan, brown hyperpigmented, blue grey hyper-
pigmented and normal colour.  
3. Blur Vitiligo  : 
 This corresponds to vitiligo macules occurring in the sites of post 
inflammatory hyper melanosis. 
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4. Inflammatory Vitiligo : 
 This has an erythematous raised border similar to that seen in tine 
a versicolor. 
5. Confetti Macules  : 
 This is seen as multiple vitiliginous macules of 1-2 mm 
diameter28. 
PSORALEN    PHOTO-CHEMOTHERAPY 
 Psoralen photo – chemotherapy is by which psoralen and UVA 
are used to bring beneficial responses to patients suffering form vitiligo.  
Such beneficial responses are not produced by the drug or radiation 
alone2. 
HISTORICAL BACKGROUND 
 Psoralen   and its derivatives are naturally occurring tricyclic furo 
coumarins found in more than thirty plants such as lime, lemon, 
bergamot, fig cloves, and babache2. 
 The ancient Egyptians and Indians used plant extracts and applied 
to the skin or administered orally in combination with sunlight to 
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produce photo toxicity in vitiliginous skin with subsequent 
repigmentation in 1400 B.C7. 
 The most widely used plant derivatives in photo – chemotherapy 
are 8-MOP produced by the plant Ammmi Majus, Ficus carica.  5 MOP 
is also known as Bergapten, majudin and Heraclin. This is also produced 
by citrus and psoralea corylifolia.  These psoralen are present in the 
leaves, fruits, seeds, roots, and the rhizome of the plants3.  
In 1940 – Isolation of psoralen from Ammi Majus was done7. 
In 1947 – El Mofti et al showed the psoralen’s therapeutic 
efficacy in vitiligo2. 
In 1950- Both topical and oral psoralen was used in vitiligo7. 
In 1954- a Pharmacologic study of psoralen by Pathak and 
Fitzpatrick in the Unites States and by Musajo and his collaborators in 
Italy was done18. 
In 1960- Synthetic furo coumarin trimethyl psoralen was used in 
the treatment of vitiligo18. 
In 1974- Artificial UVA after oral administration of 8 MOP in 
psoriasis was called acronym PUVA by Parrish et al2.  
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In 1988 – NUVB was discovered by Van Waden et al and Green 
et.al. 
In 1997 – Westerhof and Nieweborers first used NBUVBin 
Vitiligo66. 
TYPES OF PSORALEN AVAILABLE ARE: 
1) Natural       – 8 Methoxy psoralen (8 MOP) 
5 Methoxy psoralen (5 MOP)3. 
2) Synthetic     – 4,5,8, Trimethyl psoralen 
3 carbethoxy psoralen (3 CP)21 
8 Methoxy Psoralen  (8MOP)   
It has molecular weight of 216 .2 and occurs as a white to cream 
coloured, odourless solid that forms needle like crystals. It is soluble in 
acetone, acetic acid, propylene glycol and benzene. It is sensitive to air 
and light and is easily hydrolysed.  Its melting point is 148 ° C. 
Psoralens are lipophilic, non ionized compounds, very poorly soluble in 
water and ether20. 
This poor solubility impedes their absorption from the stomach 
and the intestine. A micronized crystal in gelatin capsules is more 
rapidly and completely absorbed. Fasting condition increase psoralen 
absorption. Fatty meal decreases its absorption and delays its peak level.  
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Medication should be taken with water only.  Ideally food should be 
avoided until after the treatment70. 
High level of psoralen in blood under fasting condition can cause 
nausea which can be alleviated by taking along with food or milk18.         
After absorption psoralen exhibits peak serum level between 1 
and 6 hours2. It also exhibits strong but saturable first pass effect 
through the intestines and the liver70. 75-85% of methoxalen  is 
reversible, bound to serum albumin and 98-99% in case of 5 MOP (5 
Methoxypsoralen) Epidermal cell binding is about  90% in case of 8 -
MOP, 79%  in case of 5- MOP studies have shows that psoralen spreads 
rapidly to most organs but binding seems to be short lived and 
reversible, provided that there is no exposure to UVA irradiation70. 
8-MOP is completely metabolized in the liver and oral 8-MOPhas 
serum half life approximately 1 hr and it is rapidly eliminated. There 
appears to be no accumulation of metabolites. Hence repeated dose does 
not cause significant accumulation of the drug in the body.  After 
ingestion of psoralen, the skin is most sensitive to UVA after  1-3 hours 
but  remain active upto 8-12 hours2. 
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The drug is completely excreted in 12hours (80% in 6-8 hours 
and 90% in 12hours)2 
The unpredictable pharmaco kinetic behaviour is probably due to 
large inter individual and small intra individual variation in absorption 
and bio availability12. Eventhough psoralen appears to be distributed to 
all cell organs, photochemical binding occurs only in the skin , eye and 
blood71. 
8-MOP is taken orally as a capsule in a dose of 0.6 to 0.8 mg/ kg 
bodyweight, one to two hours before exposure to UVA radiation3.  
In general, 0.4 mg /kg bodyweight is recommended because of 
more predictable absorption, lower incidence of nausea and one hour 
interval is more convenient for patient and cost saving70. 
The liquid methoxalen formulation provides more rapid, higher 
and more reproducible peak serum level than crystalline formulation18. 
Tolbutamide displaces 8-MOP from its binding site and enhance 
photosensitivity2. 
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MECHANISM OF PSORALEN’S ACTION 
          Photo activated psoralen is mostly confined to skin and eye, thus 
PUVA represents a form of target related chemotherapy. The exact 
mechanism by which photo sensitivity occurs following PUVA is not 
precisely known.    The absorption of psoralen maxima lie in 210- 310 
nm. The action spectrum for oral PUVA is probably in the range of 320- 
325 nm.   In psoralen treated skin, on exposure to UVA rays, two 
distinct reactions take place7. 
TYPE 1 –ANOXIC REACTION  
The site of cellular damage is primarily the DNA of the cell 
nuclei by forming mono functional and bi functional adduct in the DNA 
of melanocytes, there by increasing G2 phase of the cell cycle in which 
Melanocyte Stimulating Hormone (MSH) receptors are more active33,18. 
TYPE 2  
It is oxygen dependent and forms free radicals .In this type, 
reactive form of the psoralen in its triplet state and the site of these 
reactions are DNA, chromatin, cell membrane of epidermis, dermal 
endothelial cell, cytoplasmic constituents of melanocytes which cause 
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release of IL-1 and facilitate the binding of keratinocytes  to more α 
MSH receptors7.  
Amelanotic melanocyte in hair follicle was discovered by 
Staricco in 1959. The mechanism by which melanocytes repigment was 
further elucidated by Orfonne et al and Cui et al63. 
PUVA causes repigmentation by activation of the inactive 
melanocytes in the middle and the lower part of hair follicle and hair 
root sheath. Inactive melanocyte contains only structural melanosomal 
protein but don’t contain enzymes required for melanogenesis63. 
PUVA suppresses number of functional blood peripheral 
lymphocytes, polymorphic mononuclear lymphocytes, macrophages and 
T cell, diminished mitogen response showing beneficial effect within 
immune reaction by reducing Langerhan cells 6 to 7 days after PUVA 
and change in number and morphology of above cells and return to 
normal by 14 days after stopping PUVA2. 
El Mofty proposed the mechanism by which psoralen induces 
pigmentation.  
1) Release of inhibited tyrosinase enzyme31.  
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2) Induction of migration of active melanocytes from the 
surrounding normal epidermis and hair follicle by inflammatory 
mediators such as Leukotriene C4 (LTC4), Leukotriene D4 
(LTD4) , TGF α, melanocyte growth stimulating factor which are 
released by keratinocytes secondary to UV damage7. 
3) Increased tolerance to UVR / solar exposure and thereby stronger 
stimulation  of melanocytes7. 
4) Correction of abnormalities of structure of melanocyte in 
vitiliginous skin7.  
5) Reactivation of inactive melanocytes in vitiliginous patch7.  
PUVA increases denova expression of SA beta galactosidase, a 
marker of fibroblast senescence in vitro and vivo which result in 5 to 8 
fold upregulation of matrix metaloproteinase I, III and result in 
premature aging26. 
 UVA exposed kertinocytes express 2 factors (P-1, P-2),.  with 
molecular weight 20KDa, 1 KDa respectively. Its stimulates DNA 
synthesis in human keratinocytes by expression of cytokines like IL6, 
IL8, Granulocytes / macrophages colony stimulating factor11. 
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PUVA treatment may deplete vitiligo associated melanocytic 
antigen (VAMA)68.  PUVA inhibits ‘S’ phase of cell cycle57.  
ULTRA -VIOLET RADIATION 
           Ultra violet radiation is a part of spectrum of electro magnetic 
radiation. Wave length less than 290 nm are absorbed by ozone layer 
which is about 25- 30 km above the earth’s surface. The wave length 
less than 260 nm are absorbed by cellular protein and wave length of 
280nm are absorbed by cellular nucleic acid , causing cell damage and 
cell mutation45.  
            Absorbed by ozone                             Reaches earth’s surface 
  
         
                                                                 
UVC                              UVB                                      UVA 
          
200 nm                     290 nm               320 nm                          400nm 
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UVA  0 200-290 -- ++
+ 
+++ -- Epidermis 
UVB 1.7 290-320 -- ++ ++ ++ Epidermis + Papillary 
dermis 
UVC  6.3 320-400 + + + + Papillary + reticular 
dermis 
Visible  9.2 400-800 + -- -- + Reticular dermis + 
subcutaneous Fat 
Maximum UVL reaches the earth at noon because of the 
transverse passage of rays.  More UVL reaches the earth in summer50. 
Solar radiation that reaches the earth is either reflected, transmitted or 
attenuated by gas molecules and water droplets at 330 nm, by 
stratospheric ozone absorption between 200 to 330 nm and by oxygen 
below 200nm27. 
UV rays are reflected by snow (85%), sand (25%), dribbling 
water (5%), decreased by cloud 20-90%,  60% by every 50 cm traveled 
through water27. 
UVC  is totally filtered by atmospheric ozone and is not present 
in sunlight. It can be artificially produced by the use of filters.  Artificial 
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source of UVC is cold quartz. They are inexpensive, do not need time to 
warm up or cool off. UVC is mutagenic in vitro, effectively killing 
micro organisms in the immediate vicinity. It is used for sterilizing 
environment in the operating rooms. Desquamating effect of UVC have 
been used to treat acne patients. UVC does not promote skin 
pigmentation, but it does cause an immediate burning sensation and 
desquamation 24 to 48 hours after treatment.  It has the highest energy 
part of the UV radiation38,27. 
UVB (290-320nm) 
It is referred to as sunburn spectrum because exposure to this 
causes sunburn and delayed tanning. In addition, certain individuals 
react abnormally to solar radiations such as urticarial papules, vesicles, 
plaque etc33. 
UVA (320-400nm) 
It causes depletion of antigen presenting cell and induces 
transient and less effective immune suppression. UVA rays can 
penetrate the skin deeply upto subcutis and trigger the production of 
melanin causing immediate tanning and premature ageing, stratum 
corneum thickening and epidermal hyperplasia55. On earths surface the 
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ratio of UVA to UVB 20:127. UVA is strongest between 10 A.M.  and 4 
P.M.  This is not absorbed by unstained glass and has the lowest energy 
of UV radiation38.  UVA increases skin temperature to cause pain at  
42° C and immediate pigmentation between 6 and 20 j/sq. cm23.  UVA is 
sub-divided into UVA 1 (340-400nm) and UVA 2 (320-340nm). 
Biologically speaking, UVA 2 is more effective than UVB27.  
The psoralen photo chemotherapy action spectrum is UVA 
portion of eletro magnetic spectrum.   
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PHOTOTHERAPY UNITS 
 PRINCIPLES OF PHOTOTHERAPY : 
UV radiation is produced artificially by the passage of electric 
current through a gas, usually vaporized mercury. The mercury atoms 
become excited by the collision of electrons flowing between the lamp’s 
electrodes. The excited electrons return to the particular electronic state 
in the mercury atom and in doing so they release some of the energy that 
they had absorbed in the form of optical radiation which is called as UV 
rays45. 
All bodies whose temperature is above absolute zero (Kelvin = -
273 °c) emit electro magnetic radiation. The higher the temperature, the 
more intense becomes the radiation and the greater becomes the short 
wavelength radiation components. With rising temperatures, the short 
wavelength ranges increase more strongly, and the longer wavelength 
ranges less strongly than the total radiation. 
The Stefen- Boltzmann law states that the total electro magnetic 
radiation of a body varies with the fourth power of the temperature. In 
this case, the total radiation signifies the wavelength range between zero 
and infinity.  
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TYPES OF PHOTOTHERAPY UNITS AVAILABLE: 
1) Conventional incandescent lamps  
2) Halogen incandescent lamps  
3) Discharge lamps 
4) Low pressure mercury vapour lamps 
5) High pressure mercury vapour lamps  
6) Metal vapour halogen lamps 
7) Short arc mercury vapour lamps (maximum pressure lamps) 
8) Xenon short arc lamps. 
9)  Fluorescent lamps 
DISCHARGE LAMPS : 
In this the radiation is generated when current flows through 
gases or metal vapors. The non conductive gas to a conductive state is 
done by means of high voltages which are briefly applied and are 
generated by specially designed starters or ignition systems. There are 
used for cosmetic and therapeutic applications and are intended to 
generate UV and short wavelength IR radiations simultaneously. The 
source for the UV radiation is a mercury high pressure arc tube. IR 
radiation is generated by a tungsten coil .This coil also performs  the 
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function of ballast resistance too.  Discharge lamps are supplied in many 
size and designs. 
1) Low pressure mercury lamps 
2) High pressure mercury lamps 
3) Low pressure sodium lamps 
4) High pressure sodium lamps 
5) Metal vapour lamps  
6) High pressure xenon lamps 
7) High pressure krypton lamps 
LOW PRESSURE FLUORESCENT LAMPS 
 Lamps emit radiation within UVA 350 and 370 nm. 
PROPERTIES 
Power levels, compact lamps 7-18 W 
Power level, tubes 40-100 W 
Lamp lengths, compact lamps 14 – 24 cm 
Lamp lengths, tubes 60-180 cm 
Supply voltage 125 – 230 V 
Operations Using chokes and starters or using 
electronic adapter systems. All systems 
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must be approved for the respective 
type of lamp,  
Brand Designation Light colors 78 and 79, Eversun Super, 
TL / 10,12, TL/09, CLEO. 
INFLUENCES THAT CAN CHANGE THE RADIATION OF 
A LAMP: 
Depending on the time, temperature, mechanical and electrical 
adjustments, variations of the lamp emissions can result. Sometimes also 
the bulb material will change without consequences in the visible range, 
but it is possible that by this constructive variation, the UV radiation 
will be changed. Some of these influences can ameliorate. For example, 
by prolongation of the irradiation time or by better cooling40.  
In this study, high pressure mercury vapour half body and hand 
and foot  lamps were used in the phototherapy units.  These are compact 
lamps. It contains mercury. This type of lamp is relatively economical as 
a long service life of many thousands of hours and is used widely 
nowadays in the treatment of psoriasis and vitiligo. The bulbs have 125 
– 1000 watts power45. 
The spectral emission from this type of units is from 254 nm - 
366nm peak 352 nm and emit approximately 0.5 % of UVB. High 
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pressure mercury lamps are manufactured at the power level of 125 
watt, with a so called black glass bulb which absorbs the visible lines 
and transmits only the UVA line at 366nm40,25.  
Regular broad band UVA lamps, which are manufactured for 
PUVA therapy, serve as light sources for the photo chemotherapy for 
vitiligo. These are either fluorescent lamp bulbs or metal halide lamps. If 
metal halide lamps are use, a UVB filter is required to eliminate the 
shorter wavelength portion of the emission spectrum. 
DOSIMETRY: 
The radiation energy from PUVA is converted into electrical 
energy and readout by instrument called radiometer.  It is made up of a 
radiation filter, input optical and a detector where as that at specific 
wavelength known as the spectral radiation is measured with the much 
more complex spectroradiometer which includes a monochromator 
instead of filter. The radiation dose is then calculated as the product of 
measured irradiance and the exposure in time (Sec).  Four commonly 
used are photomultiplier tube, vacuum photo tube, solid  state photo 
diode, thermopile.  Photo multiplier tube are very sensitive but fragile.  
Solid state photodiodes are more robust, small and suitable for rapid 
portable radiometry (eg) phototherapy equipments.  Thermopile are 
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small robust, have flat spectral responses are best for the quick accurate 
measurements of monochoromatic irradiance or of serial broad band 
irradiance of fixed spectral content. 
 The dosimetry of photochemotherapy of vitiligo needs always to 
be done with special care because over exposure may result in serious 
adverse reactions. There are no parameters that allow a reliable 
prognosis for an individual patient. It has been demonstrated that after 
PUVA treatment, the majority of the patients retain PUVA induced 
repigmentation for many years. Neither the pathogenesis of vitiligo nor 
the mechanisms of regimentations by photo therapies are completely 
understood3,18. 
UV radiation is present in sunlight also. In vitiligo, 8-MOP is 
conjugated with sunlight exposure is called as PUVASOL therapy2. 
The exposure done is done in outdoor between 10 am to 3 pm, 
two or three times per week .It is never done on consecutive days. Sun 
exposure is initially limited to five or ten minutes for Type 1 / 2 or 3 and 
greater skin types respectively, increasing by five minutes with each 
exposure. At that time a gradual increase is allowed based on redness 
and tenderness for upto two hours45. The disadvantage of therapy is 
difficulty in quantifying UV rays and total amount of UV rays may also 
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vary according to the season, time of the day, latitude and condition of 
atmosphere7. 
The irradiation of light is measured in milliwatt/cm2 with the 
help of an approximately calibrated radiometer .The dose of UVA 
irradiation is employed to calculate the exposure time for the desired 
dose in Joules.  
Energy (joule) = Power(watt) Χ exposure time (second) 
Fluence (J/cm2 = irradiance (W/cm2) Χ exposure time (sec) 
                                             Prescribed UVA dose (J/m2)  
  Exposure time (mts) =        
                                             0.06 irradiance (mw/cm2)    
 
VARIATION OF IRRADIANCE. 
Irradiance (power density) varies directly with power source and 
inversely with surface area (therefore inversely with the square of 
distance from the power source. 
11 Χ D12= 12 Χ D22 ( I= irradiance; D= distance) 
D12 /  T1 = D22  /T2 ( T= exposure time) 
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Grading of erythema 
E0  - No erythema 
E1  - Minimally perceptible erythema (faint pink) 
E2  - Marked erythema (red) 
E3  - Fiery red erythema with oedema 
E4  - Fiery red erythema with oedema and blistering 
In pigmented patient, sometimes erythema and oedema may not 
be seen.  Instead of these, patient may complain of hotness and tightness 
of skin.  
Erythema is a limiting factor in phototherapy – E1 should not be 
exceeded. The onset of UVA – induced erythema has a delayed onset of 
48 hours after exposure. 
MPD (Minimal phototoxic dose ) = The dose of PUVA required 
to produce a E1 reaction 48 hours after exposure. 
MED (Minimal erythemogenic dose) = The dose of UVB 
required to produce a E1 reaction 24 hours after exposure13. 
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MPD  is can be accomplished by using a template with six to 
eight 2 x 2 cm squares cut out and applied to a sun protected area, such 
as the buttocks.  After the rest of the patient’s skin is shielded with 
appropriate UV opaque covering, graduated doses of UV light can be 
delivered to the test site by sequentially blocking the template openings 
with opaque material at increments designed to produce an array of UV 
light exposure lightly less or greater than the expected MED or minimal 
phototoxic dose based on the patient history.  This is done after 
administering the photosensitizer (1½ - 2 hrs) after oral psoralen and 1 
hour after topical psoralen5.   
          Usually the first dose range from 0.5 to 5 J /cm2. Minimum 
Phototoxic. Dose (MPD) thus determined indicates the first therapeutic 
UVA dose for the follow up and adjustment of the dose, determination 
of photosensitivity, pigment index (PDI) become necessary. This is done 
by reading the erythema and pigmentary reaction after 72 hours and 120 
hours in the first test field exposed for MPD determination. The PDI 
serves to assess the patient’s capacity to develop the tolerance to photo 
toxic reaction by pigmentary reaction of the skin18,3. 
Perifollicular pigmentary dots were the first to appear followed 
by the hyperpigmentation of the border. Dots of pigmentation usually 
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develop after 20 to 30 exposures. , 50 exposures on trunk and proximal 
extremities, and near total repigmentation usually requires 50 to 300 
exposures8.  
VARIOUS SCALES IN PUVA ASSESSMENT  
1) Based on RULE OF NINE39 
2) Assessment scale proposed by Hossain17 
Parameter -- + ++ +++ ++++ 
Change in 
colour 
No change Yellowish tint Slight contrast 
between lesion 
color and 
surrounding 
skin colour 
No contrast 
between lesion 
color and 
surrounding 
skin colour 
100% 
remission 
in all 
treated 
lesions 
Change in size NO change Up to 5mm 
reduction in 
diameter 
Up to 10mm 
reduction in 
diameter 
More than 
10mm 
reduction in 
diameter 
 
Folliculocentric 
repigmentation  
No 
repigmentation. 
Upto 5mm 
perifollicular 
repigmentation
Upto 10mm 
perifollicular 
repigmentation
More than 
10mm 
perifollicular 
repigmentation. 
 
 
3) Vitiligo Area Severity Index69 
The percentage of vitiligo involvement is calculated in terms of 
hand units.  One hand unit (which encompasses the palm plus the volar 
surface of all digits) is approximately equivalent to 1% of the total body 
surface area. The degree of pigmentation is estimated to the nearest of 
one of the following percentages : 100% - complete depigmentation, no 
pigment is present; 90% - specks of pigment present; 75%- depigmented 
area exceeds the pigmented area; 50%- pigmented and depigmented area 
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are equal; 25% - pigmented area exceed depigmented area; and 10% - 
only specks of depigmentation present.  
The VASI for each body region is determined by the product of 
the area of vitiligo in hand units and the extent of depigmentation within 
each hand unit measured patch. Total body VASI =Σ all body sites 
(Hand Units0 x (Residual depigmentation) Vitiligo disease activity score 
(VIDA). The VIDA is a six-point scale for assessing vitiligo activity. 
Scoring is based on the individual’s own opinion of the present disease 
activity over time. Active vitiligo involves either expansion of existing 
lesions or appearance of new lesions.  Grading is as follows : VIDA 
score +4- activity of 6 weeks or less duration : +3 – activity of 6 weeks 
to 3 months; +2- activity of 3-6 months ; +1- activity of 6-12 months; 0 
– stable for 1 year or more; and – 1- stable with spontaneous 
repigmentation since 1 year or more. A low VIA score indicates less 
activity. 
ADVANTAGE OF SYSTEMIC PUVA OVER TOPICAL PUVA:- 
• Oral PUVA treatment is less laborious and time consuming than 
topical PUVA. 
• Erythema and blister formation is less commonly seen than topical 
PUVA. 
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• Improvement is more regular than with topical PUVA39. 
PUVA and HIV Infection 
Systemic PUVA can be safely used for the treatment of HIV 
positive infected patients and is a practical regimen with little or no risk 
of disease transmission and well accepted by the patients. But for more 
advanced HIV infection systemic PUVA is not recommended47. 
DISADVANTAGES :- 
Systemic side effects such as nausea, vomiting, carcinogenic 
effects, and cataracts are more common with oral PUVA21. 
PUVA has been shown to effect immune reactions. PUVA also 
has possible effects on the function of polymorpho nuclear leucocytes, 
formation of antibodies, immune complexes and induction of auto 
immune diseases. PUVA treatment should be closely monitered for 
induction of LE47.            
INDICATION FOR PUVA IN VITILIGO 
1. Generalized vitiligo ( more than 20 % of body surface area)46 
2. Segmental vitiligo  
3. Acral vitiligo14 
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4. Acro facial vitiligo 
5. No response to topical medication3. 
CONTRAINDICATION FOR PUVA IN VITILIGO 
ABSOLUTE:- 
1) Bloom’s syndrome 
2) Trichothiodystrophy. 
3) Previous melanoma 
4) Xeroderma pigmentosum. 
5) Systemic lupus erythematosus. 
6) Cockayne’s  syndrome 
7) Gorlin′s syndrome47 
RELATIVE CONTRAINDICATIONS:-47 
 
 
♦Age <10 years  •Age < 16 years 
♦Concurrent Malignant disease  •Cataract 
♦Concurrent Immuno Suppression •Bullous Pemphigoid, pemphigus 
vulgaris 
♦Pregnancy , Lactation • Significant Hepatic dysfunction 
♦Porphyria                                         Previous internal malignancy 
♦Previous Exposure to arsenic and 
X rays 
 
MINOR MAJOR 
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SIDE EFFECTS OF PUVA14,15,70,71, 
Acute clinical side effect :-  
These are due to the drugs (photo toxic reactions) 
1) Erythema 
2) Pruritis 
3) Koebnors Phenomenon 
4) Severe pain in the skin 
5) Drug eruptions 
6) Nausea , headaches, bronchial hypersensitivity 
7) Phyto photo dermatitis 
8) Ankle edema 
9) Blister. 
DUE TO METHOXSALEN ALONE :- 
Gastro intestinal disturbance, CNS disturbance like headache, 
dizziness, light headedness, depression, insomnia, feeling of detachment 
from the environment. Bronchoconstriction, hepatic toxicity and drug 
fever71. 
CHRONIC SIDE EFFECTS :- 
• Hyper pigmentation and xerosis14  
• Premature ageing and wrinkling54 
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• Hyper trichosis2 
• Nail changes – pigmentation, subungual hemorrhage43. 
• Precancerous skin conditions – actinic keratosis15, seborrhoeic  
keratosis , Keratoacanthoma , Bowen’s disease2. 
• Cutaneous malignancy like squamous cell carcinoma, 
melanoma36,48,65.  
• Aggravation of underlying skin disease like seborrhoeic dermatitis, 
acne, bullous pemphigoid, lupus erythematosis, cataract, 
disseminated superficial actinic porokeratosis, hepatotoxicity, 
nephrotic syndrome and exacerbation of gouty arthritis1,2. 
COMBINATION OF TREATMENT UTILIZING PUVA :- 
PUVA PLUS TOPICAL THERAPY   
                   PUVA  + Calcipotriene70 
                   PUVA  + Steroids  
                   PUVA + Minoxidil 
                   PUVA + Anapsos 
                   PUVA  +Autologous split skin graft3 . 
PUVA treatment can be divided into two phases ,  
1. The clearing phase.  
2. Maintenance phase. 
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The clearing phase begins with the commencement of therapy 
and ends with clearing of atleast 95 % of treatable lesions. 
The maintenance phase on the other hand is subject to 
considerable variations in frequency and duration as well as dose 
adjustment. 
The determination of the starting UVA dose has been classically 
dependant on the establishment of skin type in the United States and 
whereas in Europe, it is based on minimal phototoxic dose (MPD) and 
in some instances the photopigmentary index of each individual (PPI) 
.The Austrians use  MPD or the combination of MPD and 
photoPigementary index18.   
FITZPATRICK SKIN TYPE21 
Code Description 
I Always burn , never tans 
II Always burn , tans minimally 
III Burn moderately, tan gradually 
and uniformly (light brown) 
IV Burn minimally , always tan well 
(moderate brown) 
V Rarely burns , tans profusely (dark 
brown) 
VI Never burns , deeply pigmented 
(black) 
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 UVA Exposure according to Skin Type           
Recommended 
Skin Type 
Initial Maintenace Dose 
(J/cm2) 
Increment dose 
(J/cm2) 
1 4-6 0.5-1 2.5-5 
2 6-8 1-2 0.5 
3 8-10 1.5-3 0.5-1 
4 10-12 2-4 1 
5 12-14 2.5-5 1 
6 14-16 3-6 1-1.5 
 
The dose of UVA is increased from 0.5 –1 J /cm2 depending on 
the skin type or an individual response. The treatment is given usually 
two to three times weekly atleast 48 hours apart to permit evaluation of 
any erythema resulting from preceding treatment. If painful eythema and 
blister persist and wide spread, the treatment should be restarted, once 
the lesion completely subsides and restarted at minimal dose lower than 
the previous treatment dose. If still erythema occurs, artificial UVA dose 
or sunlight exposure should be withheld constantly. Marked erythema  
due to photo toxicity should be avoided since subsequent koebnerization  
may cause reversal of repigmentation . 
During the UVA irradiation, protective eye goggles should be 
worn. Clothing should not be worn and sun screen should not be used 
before UVL exposure. During UVL treatment, protection of face with a 
pillow case and male genitals with an athletic support is often advised. 
The patient should be advised to avoid exposure to sunlight for 8 hours 
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after taking UV light treatment. If exposure is unavoidable skin should 
be protected by clothing, hat, and sunscreens that block UVA18,24.  
Maintenance  schedule  
The final clearance dose of irradiation is held constant and the 
frequency of treatment is gradually reduced as follows. 
Four treatments at weekly interval 
Then, 
Four treatments every other week 
Then, 
Four treatments every third week 
Then, 
Four treatments  every fourth week 
Then , 
Stop treatment or continue monthly treatment70 
Special glasses should be worn to protect the eyes even when 
indoors; window glasses may not shield UVA light. Hence protective 
eyewear must be worn, lubricating lotion / Emollient lotions can be used 
for dry skin following the treatment18. 
If regimentation is not seen even after 20 – 30 treatments, the 
dose of 8 MOP can be increased. If still desired results are not achieved 
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after another 20 – 30 treatments, the treatment is to be viewed as a 
failure13. 
If treatment is interrupted before an area gets completely 
repigmented, the area once again becomes depigmented within a short 
time . Psoralen therapy also increase the tolerance of affected skin to 
sunlight possibly through thickening of the stratum corneum3. 
TOPICAL PUVA. 
If vitiligo macule is less than 6 cm2 in size, 0.1 % of psoralen 
lotion can be applied weekly followed by one and half to two hours later 
exposed to sunlight for 30 – 60 seconds. And duration can be increased 
by 30 seconds per sitting until light erythema occurs on the day 
following the exposure. Alternatively the area is exposed to black light 
source at a distance of 4 cm for 4-5 minutes. Initial exposure dose is 0.5 
J/cm2, with increment of 0.25 –0.7 J/cm2 in the subsequent treatment 
until a light pink colour is obtained. After treatment exposure, the area 
should be washed with soap and water and covered with a clothing or 
with a sunscreen3,18. 
Other modalities available are  :- 
• Bath PUVA and Bath suit PUVA. The advantage of this method is 
systemic toxicity can be avoided18. 
• 5- MOP ( 5 Methoxy Psoralen) 
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        A dose of 1.2 –1.8 mg /Kg body weight is said to be as effective as 
8- MOP when given at a higher dose or a high dose of UVA radiation . 
Side effects are less and decreased phototoxicity due to decreased 
concentration in the epidermis2,34.  
• Trimethyl Psoralen (4, 5, 8 MOP) is often used topically and orally21. 
• 3 Carbethoxy Psoralen (3 CP) may be therapeutically effective but 
less phototoxic than 8 MOP in humans18. 
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METHODS AND MATERIALS 
Forty one patients of either sex with stable generalized type, 
acral, acrofacial type of vitiligo with > 20 % of body surface area 
involvement were enrolled for the study after obtaining the informed 
consent. History included the following: 
1. Age of onset of depigmentation 
2.  Course of the disease – stability, rate of progression 
3.   Potential precipitating events including emotional stress, 
cutaneous trauma 
4.  Any history of photosensitivity 
5.  Ocular or auditory dysfunction 
6.   Family history of vitiligo and early graying of hair 
7.   Personal or family history of autoimmune diseases 
       All patients were examined under good light. Importance for 
the distribution, number of lesions, colour of lesions, the affected sites in 
the skin,approximate surface area of depigmentation, pattern of vitiligo 
and mucosal involvement were taken into account. Any presence  of 
leukotrichia  in the patch were noted. 
Any associated autoimmune disorders if present were noted . 
Laboratory investigations like routine blood examination ( Hb, TC, DC, 
ESR), urine analysis, liver function tests, thyroid profile were done.  
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Blood group, peripheral smears, blood sugar, serum creatinine were also 
done . 
INDICATIONS OF PUVA –INCLUSION CRITERIA 
1) Generalized stable vitiligo  
2) Acro facial vitiligo 
3) Acral vitiligo  
4) Patient who has given consent for clinical photo and treatment  
EXCLUSION CRITERIA 
1.  Patient not willing to give written consent 
2.  Patient below 12 years and above 60 years  
3.  History of photo sensitivity and photo sensitive skin disorders  
4. Pregnancy and lactation  
5. Concurrent immuno suppressive and premalignant skin disease 
6. Significant hepatic and renal dysfunction  
Audiograms were done to rule out any sensory neural deafness. 
Fundoscopy was done to rule out cataract and retinal pathology .Clinical 
photographs were taken for all the patients before and after exposure to 
PUVA therapy. This study was randomized single blinded age and sex 
matched.  
In each case initial lesions on both sides of the body were 
assessed with the Rule of Nine.  8 -MOP tablets were given according 
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to the weight of the patient .After one and half to two hours the patients 
were subjected to UVA exposure artificial phototherapy chamber 
starting with a dose of 4 J /m2 over whole body. 
An increase of dosage by 0.5J/cm2 was done provided there was 
no generalized erythema or other side effects. Comparative assessment 
of index lesions was done on each side in each case before starting 
treatment and after every five exposure to UVA treatment for a period of 
8 – 10 months.. 
METHODOLOGY 
8 MOP tablets are given in the following doses (which is equal to 
0.4 – 0.6mg./ kg body wt.) 
Patient’s Weight (Kg) Dose in Mg. (1 tab – 10 mg)70 
> 30 10 
30-60 20 
65-90 30 
> 90 40 
Drugs was taken in the empty stomach because of its absorption                 
was enhanced. If patient complained  of nausea the tablets  were taken 
after a small meal. Subsequently after 1 ½ -2 Hrs, the patient’s whole 
body was irradiated with UVA by an appropriate irradiation system. The 
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starting dose (Joule) was  determined by Fitzpatrick skin typing. As the 
Indians belong to Fitzpatrick’s Skin typing V, started at 4J/Sq.cm70.   
Repeated exposure for 2 times/week was done to clear PUVA 
responsive disease. Increment dose of 0.5 joules/sq.cm/1-2week during 
each exposure was based on the patient’s response14. 
During treatment the eyes were protected by wearing UV – 
blocking goggles. An occasional exception was made in patients with 
recalcitrant disease of the eyelids or periorbital skin, and at the 
physician’s discretion40. 
Before and after treatment with photochemotherapy, a) Patients 
were advised to wear UVA – blocking glasses, whenever using sunlight 
for illumination, from the time of exposure to psoralen until sunset that 
day.  In addition, patients were encouraged to wear UV – blocking 
glasses when exposed to sunlight on the following day.   
Patients were advised to should avoid unnecessary exposure to 
sunlight on days they, receive treatment and were discouraged from 
deliberate exposure to sunlight on nontreatment days. Patients were  
encouraged to use sunscreen on exposed areas. 
When trace of erythema was seen after 72 hrs, dose was not 
increased and patients were treated with previous exposure time if side 
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effects were noted.  When more than 95% clearance was obtained, the 
last dosage was maintained and maintenance schedule was given. The 
patients were assessed every fortnightly and values tabulated. 
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RESULTS  
TABLE 1 
OVERALL RESPONSE RATE 
Data Mean SD Minimum Maximum 
Age  41.27 11.45 18 60 
No .of patch   27.73 8.58 15 50 
No. of  month  94.07 66.62 12 240 
Extent of  lesion 31.05 10.27 15 60 
% of area involved 34.03 11.02 15 60 
 No.of sitting 57.67 30.67 5 100 
 Last visit 19.17 7 10 35 
 
 
TABLE 2 
TYPE OF VITILIGO 
Type Total patient Percentage 
     Generalized               20           66.7 % 
          Acral               5          16.6% 
      Acro facial               5          16.6% 
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TABLE 3 
AGE RESPONSE TO PUVA 
Generalised type-
Vitiligo 
Vulgaris 
Acral Acro Facial Age 
(yrs) 
M F Response M F % M F % 
10-20 -- 1 75 -- -- -- 1 -- 58 
21-30 2 -- 63.5 2 1 43.6 -- 1 11 
31-40 1 5 44 -- 1 50 -- -- -- 
41-50 3 3 36.7 -- -- -- 3 -- 42.6 
51-60 4 1 57.45 1 -- 25 -- -- -- 
 
Overall response Vitiligo Vulgaris Acral Acrofacial 
Female 50.7 % 50.00 % 11.1 % 
Male 60.6 % 33.33 % 46.5 % 
 
 
TABLE  4 
ACUTE SIDE EFFECTS 
a) Generalized  type of Vitiligo  
 
Symptoms No. of  Patients 
(20) 
% 
Pruritus 8 26.6 
Erythema 10 33.3 
Bulla 2 6.66 
Xerosis 7 23.33 
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b) Acral  
Symptoms No. of Patients (5) % 
Pruritus 1 3.3 
Erythema 1 3.3 
Bulla 0 - 
Xerosis 1 3.3 
 
c) Acrofacial 
Symptoms No. of Patients (5) % 
Pruritus 1 3.3 
Erythemia 1 3.3 
Bulla 1 3.3 
Xerosis 1 3.3 
 
TABLE 5 
EXACERBATION  FACTORS IN RELATION TO PUVA 
 Mild Moderate Good Excellent 
Normal  (24) 7 6 4 7 
Exacerbation  (6) 1 0 1 4 
X2     = 3.6                     p =  0.31                      NIL SIGNIFICANT 
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TABLE 6 
RELATION OF PHYSICAL AND CHEMICAL INJURY TO  
PUVA 
 Mild Moderate Good Excellent 
Normal   8    4     4     11 
INJURY   0    2      1      0 
X2  = 6.3                   p = 0.09                  NIL SIGNIFICANT 
Causes of early discontinuation  of PUVA in this study : 
1) Long Distance 4 
2) Lack of Compliance 3 
3) Fear of side effects 2 
4) Associated with DM and hypertension 2 
 Total 11 
 
TABLE - 7 
FAMILY HISTORY AND PUVA RESPONSE 
 Mild Moderate Good Excellent 
Nil 3 5 3 7 
Consanguinous marriage 2 0 1 2 
Family members 3 1 1 2 
X2  = 3.11             p = 0.38                     NIL SIGNIFICANT 
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TABLE – 8 
OVERALL RESPONSE IN VARIOUS TYPES OF VITILIGO 
Type Mild 
(<25 %) 
Moderate
(25-50 
%) 
Good 
(50- 75 %)
Excellent 
(> 75 %) 
Generalized   (20) 2 6 9 3 
Acral  (5) 1 2 2 -- 
Acrofacial  (5)      1 3 1 -- 
 
TABLE – 9 
PAIRED SAMPLES STATISTICS 
 N Mean SD Paired t-
test 
Initially involved  30 34.03 11.022 
Last visit 30 19.17 6.998 
t = 6.99 
p = 0.001 
( P  < 0.05) 
 
AGE RESPONSE IN RELATION TO PUVA 
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Nil Significant  
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DISCUSSION 
Vitligo is a disease of unknown aetiology. Though it is not a life 
threatening disease  and does not require treatment, it causes cosmetic 
disfigurement, emotional stress and  social stigma. Therapeutic 
approaches are directed to reverse the progressive loss of  pigment 
producing epidermal melanocytes and to reconstitute the normal skin 
colour. Upto 20% patients with vitiligo experience transient 
repigmentation in some skin area upon exposure to sunlight. However 
photochemotherapy can induce permanent cosmetically acceptable 
result9.  
         Aim of our study is to evaluate efficacy of PUVA treatment in 
South Indian vitiligo patients by this prospective study.  Forty one 
patients were enrolled for this study. Out of which thirty patients 
regularly took PUVA therapy. (<25% of their scheduled PUVA therapy) 
         The age of these patients ranged from 18 to 60 yrs. (mean age 
41.72+/- 11.44)  
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Sixteen male patients and fourteen female patients were taken up for this 
study giving male to female ratio of 1.2:1. Family history of vitiligo was 
found in seven patients (23.33%) of which two were acral type (1 acral, 
1 acrofacial type) and five were generalized type.  
         The types of vitiligo taken in our study were generalized (20 
patients, 66.7%) , acral in five patients (16.6%) acrofacial in 5 patients 
(16.6%).  Duration of the disease ranged from 12 months to 240 months 
(mean 94.07+/- 66.62).  The percentage of the area of vitiligenous 
patches extended from 15% to 60% giving a mean of 34.03% +/- 
11.02%.    
              The cumulative doses ranged from 20 J/cm2   to 440 J /cm 2   
with a mean of 230.4 J/cm2. Number of sessions to initiate  
repigmentation ranged from 6 to 15 sessions (8.45%) in case of 
generalized type and in case of acral and acrofacial type  8 to 18 
sessions (11%) which is comparable to the study done by James 
E.Fluton where clinical repigmentation started after two to ten 
treatments in generalized type of vitiligo30.  
              Onset of repigmentation was found to be earlier in young males 
in generalized  type and in young females in case of acral type. In 
acrofacial type it was seen in young male patients59. 
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The maintenance doses ranged from 6 to 12 J/cm2 giving a mean 
of 6.77J/cm2. When the maximum cumulative doses of 440J/cm2  (100 
exposures) was given, good response was noticed among the younger 
age groups in all three types of vitiligo. (acral, acrofacial and 
generalized types)59. 
        On following up the patients fort-nightly, initial erythema was 
noticed in 40% of patients followed by perifollicular repigmentation, 
which is consistent with the study stating that initial erythema was 
necessary for repigmentation8. (Fig. 1 & 2) 
          All the patients were assessed based on the “Rule of Nine”. In our 
study we noticed along with perifollicular pigmentation 
hyperpigmentation at the border of the patches as  reported earlier24,2. 
In generalized type, excellent response was seen in 3 patients 
(15%), good response in 9 patients (45%), moderate response in 6 
patients (30%) and mild response in 2 patients (20%). (Fig.3, 4,5,6,7,8,9 
& 10) 
In acral type good response was seen in two patients (40%)., 
moderate response was  seen in two patients (40%) and mild response in 
1 patient(20%).  (Fig. 11,12,13 & 14). 
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In acrofacial type  good response was seen in 1 patient (20%) , 
moderate response in 3 patients (60%) and mild response in 1 patient 
(20%)  
          Our study showed that analysis of factors affecting the response 
rate such as age,  koebnerisation, exacerbating factors like sunlight, 
emotion, stress, infection etc., do not affect response rate which also 
correlate the previous studies68.  
In our study , good response was found in the patients with blood 
group “O” positive but Srivastava and Shukla observed more 
predilection for the blood group “B”  and “AB”22.     
Acute side effects noticed in our study were erythema, pruritus, 
xerosis and bulla.  In generalized type, pruritus was seen in eight 
patients (26.6%), erythema in 10 patients  (33.3%) bullae in 2 patients 
(6.66%) and xerosis in 7 patients (23.33%). In acral type pruritus , 
xerosis and erythema was observed in one patient each (3.3%).  In 
acrofacial type of vitiligo pruritus, xerosis, erythema and bullae were 
noticed in 1  patient each (3.3%). 
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The mild erythema (grade 1)13 was observed  after 12 to 24 hrs. 
and subsided by 42 to 72  hrs. is compatible with previous studies, 
grading as per previous reference2. 
We found that none of the patients enrolled in the study 
developed pain and painful  erythema over the vitiliginous patches after 
80 to 100 sessions. Erythema was treated with cool compresses, 
emollient lotions and shielding of affected  area. Pruritus was treated 
with oral anti histamine,emollient and topical steroids . Bulla was 
noticed in two patients in case of generalized type of vitiligo at 
6J/cm2.The treatment was restarted after the lesions had completely 
healed at a dose  lower than the  previous treatment dose  (2J/cm2). After 
10 exposures of PUVA, 2 patients again  developed blister and therefore 
were discontinued.  Bulla was observed in 1 patient in acrofacial type at 
10J/cm2. Hence, the patient was  placed in the maintenance dose of 
8J/Sq.cm13. 
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Chronic side effects like hypertrichosis was seen in one patient of 
generalized type of  vitiligo over the patch and other long term side 
effects like cataract, premature aging and  PUVA lentigenes were not 
observed in study67. Similar to the previous study done in the UVA 
response in the vitiligo in Saudi patients.  
At the end of our study (8-10 months) bio chemical parameters 
were again repeated. None of the patients showed any significant 
changes in their blood parameters.   
In our study, trunk, face, arms, legs showed near complete 
repigmentation, while distal dorsal surface of hands, feet, tips of fingers, 
palms and soles , nipples bony prominences rarely showed complete 
repigmentation, which is consistent with the previous study of  PUVA in 
Saudi vitiligo patients4. The patches with leukotrichia showed poor 
repigmentation21. 
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CONCLUSION 
 
 In our study, the only factor to affect the overall response rate with 
the statistical significance (P.001) was the  surface area of 
involvement was directly proportional to the total session to induce 
pigmentation (p value <0.05). 
 Our data showed that the following factors like the age of the patient, 
family History of vitiligo, Koebnerization, precipitating factors and 
the age at the onset of disease have no influence on repigmentaion, 
though the onset of repigmentation was found to be earlier in 
younger patients. 
 Hairy areas (Face, Legs, arms, trunk) were more sensitive to therapy 
while non hairy areas (mucosa, finger tips, toe tips, palms & soles) 
were less sensitive to therapy. 
 Generalized type was the best type to respond very well. Acral and 
acrofacial types were resistant to therapy. 
 Good response was noticed in young patients with blood group ‘O’ 
positive individuals. 
 In our study, patients with longer duration of disease showed slower 
response to therapy. 
 We conclude, that Puva is effective, safe and cosmetically acceptable 
therapy for vitiligo. 
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PROFORMA 
Name  : Age  : 
Address :                                                                      Sex  : 
Occupation : 
1) Complaints : No. of patches, Sites 
2) Durations : 
3) Activity : Progressive, Static, Spontaneous repigmentation 
4) Factors exacerbating - seasonal, emotional, infections, drugs, sunlight 
5)     History of Injury -         Physical - present / absence 
Chemical - present / absence 
6)     Associated Visual disturbance / Deafness 
7)     Family History -    Consangunity in parents 
Other family members affected with Vitiligo 
Associated diseases in the family 
8)     Treatment History -  Ayurvedic 
Homeopathic 
Allopathic  
No treatment 
9)     Associated autoimmune diseases : 
1) Hypothyroidisrn 5)      Rheumatoid arthritis 
2) Hyper thyroidism                              6}     Alopecia areata 
3) Pernicious anaemia 7)      Addisons disease 
4) Diabetic mollitus 0)       Atopic Dormntilis 
10)   Examination (sites; 
Sun exposed  
Covered area  
mucosa   -  oral, genital, scalp  
palm / sole  
leucotrichia  
Loebner's phenomenon 
11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Local  
Focal 
mucosal 
segmental 
Whole body /  Hand + Foot 
Generalised 
vitiligo vulgaris 
Acrofacial 
universalis 
15)   General Examination  
Anaemia  
Jaundice  
cyanosis  
clubbing  
Lymphadenopathy 
12)   Extent (%) 
type of vitiligo 
14)   PUVA 
 16) Systemic Examination  : CVS   : 
      RS  : 
      Abdomen : 
17) Particulars : 
 Date of Visit 
 Weight  
 Height 
 Pulse Rate 
 Blood Pressure 
 
16) Investigations : 
1) Hb         
2) TC         
3) DC         
4) ESR         
5) Peripheral Smear         
6) Blood grouping         
7) Blood Sugar         
8) Blood Urea         
9) Serum Creatinine         
10) Liver Functin Test         
SGOT         
SGPT         
Alkaline phosphatase         
Total bilirubin         
 
 
19) Psoralen Dose : Oral / topical application 
 
20)  
Date of 
Visit 
Dose f 
UVA 
Side 
effects 
New 
Lesions
Old Lesions Repigmentation
    Stat Worsen Better  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
  
ABBREVIATIONS 
 
TGF - Transfer Growth Factor 
IR - Infrared  Radiation 
IL6 - Interleukin 
UVA - Ultraviolet A Rays 
UVB - Ultraviolet B Rays 
UVC - Ultraviolet C Rays 
DM - Diabetes Mellitus 
CLA - Cutaneous Lymphocytic Antigen 
  
 
 PUVA CHAMBER 
BEFORE 
ILLUMINATION 
AFTER  
ILLUMINATION 
HAND AND FOOT PUVA 
GENERALISED TYPE OF  VITILIGO VULGARIS 
 
BEFORE PUVA (Fig. 3) 
AFTER PUVA (Fig. 4) 
GENERALISED TYPE OF VITILIGO VULGARIS 
 
BEFORE PUVA (Fig. 7) 
AFTER PUVA (Fig. 8) 
GENERALISED TYPE OF VITILIGO VULGARIS 
 
BEFORE PUVA (Fig. 5) 
AFTER PUVA (Fig. 6) 
GENERALISED TYPE OF VITILIGO VULGARIS 
 
BEFORE PUVA (Fig. 9) 
AFTER PUVA (Fig. 10) 
GENERALISED TYPE OF VITILIGO VULGARIS 
 
BEFORE PUVA (Fig. 1) 
AFTER PUVA (Fig. 2) 
ACRAL TYPE OF VITILIGO  
 
BEFORE TREATMENT  (Fig. 11) 
AFTER TREATMENT  (Fig. 12) 
 
BLISTER  
COMPLICATION 
 
ERYTHEMA  
RUPTURE BULLA 
 
EROSION AND ULCER 
 ACRAL TYPE OF VITILIGO 
 
BEFORE PUVA (Fig. 13) 
AFTER PUVA (Fig. 14) 
